Login / Signup

BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.

Sun Min LimToshio FujinoChulwon KimGwanghee LeeYong-Hee LeeDong Wan KimJin Seok AhnTetsuya MitsudomiTaiguang JinSang-Yoon Lee
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
BBT-176 is a fourth-generation EGFR inhibitor showing promising preclinical activity against NSCLC resistant to current EGFR TKIs.
Keyphrases
  • epidermal growth factor receptor
  • advanced non small cell lung cancer
  • tyrosine kinase
  • small cell lung cancer
  • stem cells
  • bone marrow